Publicaciones (474) Publicaciones en las que ha participado algún/a investigador/a

2023

  1. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  2. Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD

    Journal of the American Society of Nephrology : JASN, Vol. 34, Núm. 6, pp. 955-968

  3. Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

    Kidney360, Vol. 4, Núm. 5, pp. 659-672

  4. Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis

    Nefrologia, Vol. 43, Núm. 1, pp. 6-47

  5. Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria-Related Acute Kidney Injury in Older Patients With IgA Nephropathy

    Kidney International Reports, Vol. 8, Núm. 8, pp. 1596-1604

  6. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

    Kidney International Reports, Vol. 8, Núm. 12, pp. 2754-2764

  7. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    The Lancet, Vol. 402, Núm. 10417, pp. 2077-2090

  8. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management

    Kidney International, Vol. 103, Núm. 2, pp. 264-281

  9. Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification

    Mayo Clinic Proceedings

  10. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification

    Kidney International, Vol. 104, Núm. 6, pp. 1092-1102

  11. Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation

    Nephrology Dialysis Transplantation, Vol. 38, Núm. 1, pp. 222-235

  12. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

    Kidney International Reports, Vol. 8, Núm. 4, pp. 860-870

  13. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    The Lancet, Vol. 401, Núm. 10388, pp. 1584-1594

  14. Targeting complement in IgA nephropathy

    Clinical Kidney Journal, Vol. 16, pp. ii28-ii39

  15. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

    The Lancet Rheumatology, Vol. 5, Núm. 8, pp. e451-e460

  16. Thrombotic microangiopathy in patients with malignant hypertension

    Nephrology Dialysis Transplantation, Vol. 38, Núm. 5, pp. 1217-1226

  17. Why should genetic testing be incorporated into routine clinical practice in nephrology? The utility of specialized clinics. An emerging need

    Nefrologia, Vol. 43, Núm. 2, pp. 161-166